BioArctic will participate at the scientific meeting “20 years of alpha-synuclein in Parkinson’s Disease and related synucleinopathies: from the bedside to the bench and back to the patient.”The conference will take place in Athens, Greece, on September 7 – 10, 2017.
At the conference, BioArctic will present the poster entitled: Characterization of h[A30P]a-SYN transgenic mice. Pre-formed alpha-synuclein fibrils introduce motor deficits and alpha-synuclein pathology.
Professor Lars Lannfelt, the co-founder of BioArctic, will represent the company in the round table discussion on the future treatment of Parkinson’s disease.
BioArctic has developed antibodies that can remove or inactivate toxic forms of alpha-synuclein. This treatment has the potential to modify the progression of Parkinson’s disease. In 2016, BioArctic entered a strategically important collaboration with the global biopharma company AbbVie aiming for a disease modifying treatment for Parkinson’s disease.
“We are looking forward to present our poster, to follow the progression in the Parkinson field and to interact with our global network,” says Gunilla Osswald, CEO at BioArctic AB.
For more information, please contact:
Gunilla Osswald, CEO, BioArctic AB
Telephone + 46 (0)8 695 6930